Vogenx Inc Common Stock Net Assets
Vogenx Inc Common Stock net assets. Based on the latest financial reports, Vogenx Inc Common Stock (VOGX) has net assets worth $-1.78 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.41 Million) and total liabilities ($3.19 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Vogenx Inc Common Stock (VOGX) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.78 Million |
| % of Total Assets | -126.28% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of Vogenx Inc Common Stock (2024–2025)
Net assets of Vogenx Inc Common Stock from 2024 to 2025. This chart illustrates how Vogenx Inc Common Stock's net assets have evolved over time, based on quarterly financial data. See Vogenx Inc Common Stock (VOGX) net asset quality to measure how much of total assets are equity-financed.
Annual Net Assets for Vogenx Inc Common Stock (2024–2025)
The table below shows the annual net assets of Vogenx Inc Common Stock from 2024 to 2025. For live market cap and overall valuation, see Vogenx Inc Common Stock (VOGX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-919.24K | -280.39% |
| 2024-12-31 | $509.58K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vogenx Inc Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 144560300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Vogenx Inc Common Stock Net Assets Breakdown (December 2025)
Vogenx Inc Common Stock net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $9.92 Million | % |
| Total Equity | $-919.24K | 100.00% |
Vogenx Inc Common Stock Competitors by Market Cap
The table below lists competitors of Vogenx Inc Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
QST International
TWO:8349
|
$259.87 Million |
|
EnviTec Biogas AG
XETRA:ETG
|
$259.88 Million |
|
Sichuan Golden Summit Group Joint Stock Co Ltd
SHG:600678
|
$259.94 Million |
|
Xperi Corp
NYSE:XPER
|
$259.95 Million |
|
Silvia, Inc.
NASDAQ:SVIA
|
$259.81 Million |
|
Tredegar Corporation
NYSE:TG
|
$259.79 Million |
|
CERRO DE PASCO RES
F:N8HP
|
$259.79 Million |
|
PharmaEngine
TWO:4162
|
$259.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vogenx Inc Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 509,584 to -919,235, a change of -1,428,819 (-280.4%).
- Net loss of 1,445,603 reduced equity.
- Other factors increased equity by 16,784.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.45 Million | -157.26% |
| Other Changes | $16.78K | +1.83% |
| Total Change | $- | -280.39% |
Book Value vs Market Value Analysis
This analysis compares Vogenx Inc Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $0.04 | $20.25 | x |
| 2025-12-31 | $-0.07 | $20.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vogenx Inc Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-216.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | -432.43% | 0.00% | 0.00x | 1.90x | $-2.25 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.35 Million |
Industry Comparison
This section compares Vogenx Inc Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $-1,986,338
- Average return on equity (ROE) among peers: -54.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vogenx Inc Common Stock (VOGX) | $-1.78 Million | -432.43% | N/A | $259.82 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $29.61 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $248.75 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $15.17 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $-10.50 Million | 0.00% | 0.00x | $834.03 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $71.77 Million | -22.23% | 0.06x | $7.56 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.55 Billion |
About Vogenx Inc Common Stock
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party pay… Read more